61 related articles for article (PubMed ID: 38743676)
1. Proteomic, single-cell and bulk transcriptomic analysis of plasma and tumor tissues unveil core proteins in response to anti-PD-L1 immunotherapy in triple negative breast cancer.
Li Y; Yue L; Zhang S; Wang X; Zhu YN; Liu J; Ren H; Jiang W; Wang J; Zhang Z; Liu T
Comput Biol Med; 2024 Jun; 176():108537. PubMed ID: 38744008
[TBL] [Abstract][Full Text] [Related]
2. Exploring novel immunotherapy biomarker candidates induced by cancer deformation.
Kim SM; Park N; Park HB; Lee J; Chun C; Kim KH; Choi JS; Kim HJ; Choi S; Lee JH
PLoS One; 2024; 19(5):e0303433. PubMed ID: 38743676
[TBL] [Abstract][Full Text] [Related]
3. Charting new frontiers: Co-inhibitory immune checkpoint proteins in therapeutics, biomarkers, and drug delivery systems in cancer care.
Xiao Y; Li ZZ; Zhong NN; Cao LM; Liu B; Bu LL
Transl Oncol; 2023 Dec; 38():101794. PubMed ID: 37820473
[TBL] [Abstract][Full Text] [Related]
4. Unlocking the Potential of Biomarkers for Immune Checkpoint Inhibitors in Cancer Therapy.
Dal Collo G; Takam Kamga P
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760473
[TBL] [Abstract][Full Text] [Related]
5. Advances in immunotherapy for triple-negative breast cancer.
Liu Y; Hu Y; Xue J; Li J; Yi J; Bu J; Zhang Z; Qiu P; Gu X
Mol Cancer; 2023 Sep; 22(1):145. PubMed ID: 37660039
[TBL] [Abstract][Full Text] [Related]
6. The deformation of cancer cells through narrow micropores holds the potential to regulate genes that impact cancer malignancy.
Choi JS; Lee SH; Park HB; Chun C; Kim Y; Kim KH; Weon BM; Kim DH; Kim HJ; Lee JH
Lab Chip; 2023 Aug; 23(16):3628-3638. PubMed ID: 37448298
[TBL] [Abstract][Full Text] [Related]
7. Overcoming acquired resistance to cancer immune checkpoint therapy: potential strategies based on molecular mechanisms.
Wang B; Han Y; Zhang Y; Zhao Q; Wang H; Wei J; Meng L; Xin Y; Jiang X
Cell Biosci; 2023 Jun; 13(1):120. PubMed ID: 37386520
[TBL] [Abstract][Full Text] [Related]
8. Tackling of Immunorefractory Tumors by Targeting Alternative Immune Checkpoints.
Dulal D; Boring A; Terrero D; Johnson T; Tiwari AK; Raman D
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345111
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in Melanoma: Recent Advances and Future Directions.
Knight A; Karapetyan L; Kirkwood JM
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831449
[TBL] [Abstract][Full Text] [Related]
10. Targets of Immune Escape Mechanisms in Cancer: Basis for Development and Evolution of Cancer Immune Checkpoint Inhibitors.
Dutta S; Ganguly A; Chatterjee K; Spada S; Mukherjee S
Biology (Basel); 2023 Jan; 12(2):. PubMed ID: 36829496
[TBL] [Abstract][Full Text] [Related]
11. Immune Checkpoint Inhibitor Therapy in Oncology: Current Uses and Future Directions:
Tan S; Day D; Nicholls SJ; Segelov E
JACC CardioOncol; 2022 Dec; 4(5):579-597. PubMed ID: 36636451
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy for Triple-Negative Breast Cancer: Combination Strategies to Improve Outcome.
Li L; Zhang F; Liu Z; Fan Z
Cancers (Basel); 2023 Jan; 15(1):. PubMed ID: 36612317
[TBL] [Abstract][Full Text] [Related]
13. Towards Novel Gene and Cell Therapy Approaches for Cervical Cancer.
Polten R; Kutle I; Hachenberg J; Klapdor R; Morgan M; Schambach A
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612258
[TBL] [Abstract][Full Text] [Related]
14. Targeting HER2-positive breast cancer: advances and future directions.
Swain SM; Shastry M; Hamilton E
Nat Rev Drug Discov; 2023 Feb; 22(2):101-126. PubMed ID: 36344672
[TBL] [Abstract][Full Text] [Related]
15. Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts.
Wang Y; Zhang H; Liu C; Wang Z; Wu W; Zhang N; Zhang L; Hu J; Luo P; Zhang J; Liu Z; Peng Y; Liu Z; Tang L; Cheng Q
J Hematol Oncol; 2022 Aug; 15(1):111. PubMed ID: 35978433
[TBL] [Abstract][Full Text] [Related]
16. Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges.
Uchimiak K; Badowska-Kozakiewicz AM; Sobiborowicz-Sadowska A; Deptała A
Clin Med Insights Oncol; 2022; 16():11795549221099869. PubMed ID: 35721387
[TBL] [Abstract][Full Text] [Related]
17. The role of biomarkers in personalized immunotherapy.
Sankar K; Ye JC; Li Z; Zheng L; Song W; Hu-Lieskovan S
Biomark Res; 2022 May; 10(1):32. PubMed ID: 35585623
[TBL] [Abstract][Full Text] [Related]
18. Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer.
Wang Y; Wang Y; Ren Y; Zhang Q; Yi P; Cheng C
Semin Cancer Biol; 2022 Nov; 86(Pt 3):542-565. PubMed ID: 35151845
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
